Yale launches study on digital health tech for cardiac patients

More articles on cardiology: Kentucky medical facility 1st in US to implant Bluetooth heart device2016 election linked to jump in cardiovascular disease, strokes at California health systemWomen most likely to pass away in decade after cardiac arrest than men, research study finds.

Jackie Drees –
Friday, October 16th, 2020
Print|Email.

Registration for the study started in September, and Yale and Boehringer strategy to hire 200 clients. The individuals will randomly be designated to use one of the three technologies over a six-month duration. All individuals will likewise get routine follow-ups with their clinic companies throughout the study.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.

The Yale Clinical and Translational Research Accelerator is dealing with German pharma company Boehringer Ingelheim to study the impact that digital health innovations have on patients with heart failure.

Through the study, Yale and Boehringer plan to analyze the impact that three various digital health technologies have on adult heart failure clients. The 3 innovations are: Bodyport, a clever scale with improved cardiac monitoring; Noom, a training app that offers tailored prepare for diet and weight management; and Conversa, an automated conversational platform that assists patients handle their health.